Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study

INTRODUCTION: Ischaemic heart disease (IHD) is one of the most common causes of death in the UK and treatment of patients with IHD costs the National Health System (NHS) billions of pounds each year. Allopurinol is a xanthine oxidase inhibitor used to prevent gout that also has several positive effe...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMJ Open
Asıl Yazarlar: Mackenzie, Isla S, Ford, Ian, Walker, Andrew, Hawkey, Chris, Begg, Alan, Avery, Anthony, Taggar, Jaspal, Wei, Li, Struthers, Allan D, MacDonald, Thomas M
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2016
Konular:
Cardiovascular Medicine
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5020706/
https://ncbi.nlm.nih.gov/pubmed/27609859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2016-013774
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller